Sanofi should learn soon whether or not the European Medicines Agency ‘s CHMP will accept the firm’s application for accelerated assessment for its sleeping sickness drug fexinidazole. The committee is this week deciding the matter, a positive outcome for the firm would bring the goal of eradicating the disease closer.
Fexinidazole would be evaluated under the Article 58 procedure for drugs intended for developing countries.








